PD-L1/TIGIT Genetic Silencing Service for CAR-T Protection

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Despite the transformative potential of CAR‑T therapy, its efficacy remains constrained by tumor microenvironment‑induced exhaustion, poor persistence, and the compensatory upregulation of immune checkpoints such as PD-L1 and TIGIT. We address these barriers through a proprietary approach that enables genetic silencing of PD-L1 and TIGIT via engineered extracellular vesicles, designed to shield CAR‑T cells from immunosuppression. Our service provides a specialized platform utilizing vesicle-mediated RNAi delivery to achieve precise and sustained knockdown of these inhibitory signals. This strategy preserves CAR‑T effector function, enhances intratumoral persistence, and reconditions cold tumors, offering a robust solution to advance your immunotherapy pipeline.

Introduction

The concurrent upregulation of PD-L1 in the tumor microenvironment and TIGIT on CAR‑T cells establishes a redundant immune checkpoint barrier that drives progressive T cell exhaustion and limits the therapeutic durability of CAR‑T therapy in solid tumors. By leveraging engineered vesicles for the targeted delivery of genetic silencers, this platform enables simultaneous, tumor-localized ablation of PD-L1 and stable knockdown of TIGIT on CAR‑T cells, thereby dismantling dual suppressive axes with high specificity while circumventing the systemic toxicities associated with conventional antibody-based checkpoint blockade.

Fig.1 Dual genetic silencing of PD-L1 and TIGIT using vesicle-based delivery for CAR-T cell protection. (Creative Biolabs Original) Fig.1 Vesicle-mediated co‑silencing of PD-L1 and TIGIT to safeguard CAR-T cells.

Our Service

Our platform offers a non-viral, biocompatible strategy to protect CAR‑T cells from immunosuppressive signals within the tumor microenvironment. Through engineered vesicles that deliver shRNA or siRNA against PD-L1 on tumor cells and TIGIT on exhausted T cells, it helps preempt functional impairment of the therapeutic cells.

What We Can Offer

We offer two complementary vesicle-based platforms for genetic silencing of PD-L1 and TIGIT, engineered CAR‑T-derived exosomes for RNAi-mediated transient knockdown and synthetic nanovesicles for CRISPR-based permanent gene editing, designed to protect CAR‑T cells from exhaustion and overcome immunosuppression in the tumor microenvironment.

Featured services of genetic silencing of PD-L1/TIGIT via vesicles for CAR-T protection at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Target cell line specifications or primary tumor samples.
Specific CAR‑T construct sequences or existing T cell subsets for compatibility testing.

Key Steps:

Workflow of genetic silencing of PD-L1/TIGIT via vesicles for CAR-T protection at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: Deliverables include a comprehensive project report outlining silencing kinetics and tumor microenvironment remodeling, along with a stock of purified engineered vesicles for functional testing.

Key Advantages

Localized Genetic Silencing with Reduced Systemic Toxicity: By utilizing vesicles to deliver RNAi or CRISPR payloads directly to the tumor microenvironment, we achieve targeted gene knockdown while avoiding the immune-related adverse events associated with systemic antibody-based checkpoint inhibitors.
Dual-Modal Platform Flexibility: We offer two complementary delivery platforms, autologous CAR‑T-derived exosomes for transient RNAi-mediated modulation and synthetic biomimetic nanovesicles for permanent CRISPR-based gene editing, enabling tailored strategies based on desired durability and safety profiles.
Intrinsic Targeting Precision: Our vesicles leverage either CAR surface protein display or anti-CD8/CD3 antibody functionalization to ensure selective homing to tumor cells and tumor-infiltrating lymphocytes, minimizing off-target editing in healthy tissues.

FAQ

Q1: How do these vesicles specifically target the tumor without affecting healthy tissue?

A1: We achieve selective targeting through a dual mechanism: tissue-specific ligands direct vesicles to tumor-associated markers, while pH-sensitive membrane components restrict payload release to the acidic tumor microenvironment. This design minimizes off-target uptake in healthy tissues and ensures that silencing agents act only at the disease site.

Q2: Can this service be combined with existing CAR-T products?

A2: Yes, our silencing vesicles are developed as a complementary strategy to work alongside established CAR-T or CAR-NK therapies. They are designed to integrate seamlessly into existing protocols, providing an additional layer of protection against tumor microenvironment-mediated suppression without interfering with the function of the therapeutic cells.

Why Choose Us?

Our platform uniquely combines precision vesicle delivery with dual genetic silencing of PD-L1 and TIGIT to safeguard CAR‑T cells from immunosuppression. By preserving effector function and enhancing intratumoral persistence, we enable robust anti-tumor activity. Choose us for a non-viral, biocompatible solution tailored to advance your immunotherapy development.

Customer Reviews

"In experimental models, Creative Biolabs' vesicle platform promoted clonal proliferation of CD8⁺ T cells within draining lymph nodes and facilitated a marked shift from an exhausted state toward a memory-like phenotype." Dr. A**n L.

"Application of Creative Biolabs' targeted silencing approach in solid tumor models enhanced CAR-T cell persistence, as vesicle-mediated delivery effectively bypassed the physical stromal obstacles that commonly impede the efficacy of antibody-based checkpoint inhibitors." Prof. M**l S.

"Creative Biolabs' PD-L1/TIGIT silencing simplified regulatory preparation by delivering critical mechanistic data on Fcγ receptor engagement and myeloid remodeling, meeting the validation criteria required." Sarah J**s.

How to contact us?

To discuss how our vesicle-based silencing platform can enhance your CAR-T programs, please contact our scientific team. We are ready to tailor a solution to your specific targets and provide detailed quotes, helping you accelerate your immunotherapy pipeline with confidence.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.